Abstract: The utility model discloses a non-adhesive detachable protective film, including the film body attached to the screen. The aforesaid film body has a soft resin layer fixed on the inner border; in which, the soft resin layer is set in strips along the edge of the border of the film body, forming a frame-sticking structure. Between the aforesaid soft resin layer and the film body, there is an adhesive layer for bonding and fixing; in which, the former one is pressed against the screen surface under pressure extrusion, forming a pressure-attached fixing structure with the screen surface. The utility model uses soft resin layer that allows the film body to be attach to the screen by extrusion, without using adhesive film. Besides, the film surface will not stick to dust when it is attached and removed in high frequency, and the fitting effect will not be reduced by repeated use.

Abstract: Disclosed herein are pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. The pharmaceutical formulations are stable and ready-to-use liposomes for the treatment of emesis and are particularly useful for treatment of chemotherapy or surgery-induced nausea and vomiting. Methods of preparation of the aprepitant formulations are also provided.

Abstract: Disclosed herein are pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. The pharmaceutical formulations are stable and ready-to-use liposomes for the treatment of emesis and are particularly useful for treatment of chemotherapy or surgery-induced nausea and vomiting. Methods of preparation of the aprepitant formulations are also provided.

Abstract: The present invention is a technical filed of pharmaceutical preparation agent, and more particular to a pharmaceutical composition containing docetaxe. The pharmaceutical composition containing docetaxe includes docetaxel and a polyethylene glycol methyl ether-polylactide block copolymer with amino acid end groups. The advantage of the present invention is subjected to a tri-block copolymer with low toxicity as the drug carrier. In addition to the pharmaceutical active ingredients and carrier, there is no other additive in pharmaceutical composition containing docetaxe. Thus, the prescription is simpler and the security is higher. In pharmaceutical component containing docetaxel, docetaxel content is more than 20%, such that the preparation process of pharmaceutical component containing docetaxel is simple, and easy for the industrial applications.

Abstract: The present invention is a technical filed of pharmaceutical preparation agent, and more particular to a pharmaceutical composition containing docetaxe. The pharmaceutical composition containing docetaxe includes docetaxel and a polyethylene glycol methyl ether-polylactide block copolymer with amino acid end groups. The advantage of the present invention is subjected to a tri-block copolymer with low toxicity as the drug carrier. In addition to the pharmaceutical active ingredients and carrier, there is no other additive in pharmaceutical composition containing docetaxe. Thus, the prescription is simpler and the security is higher. In pharmaceutical component containing docetaxel, docetaxel content is more than 20%, such that the preparation process of pharmaceutical component containing docetaxel is simple, and easy for the industrial applications.

Abstract: The invention provides a methoxypoly(ethylene glycol)-poly(lactide) block copolymer capped with phenylalanine group. The block copolymer is represented by formula (I), wherein R is acyl amine group, a=20-200, b=5-50; and molecular weights of the ethoxypoly(ethylene glycol) block component and the poly(lactide) block component respectively range from 1000-5000 and 1000-10000. The preparation method and use of the block copolymer are also provided.

Abstract: Provided are a positive electrode material for lithium ion batteries and a process for preparing the same. The positive electrode material for lithium ion batteries comprises a composite positive electrode material consists of LiCoO2 and an auxiliary positive electrode material, the general formula of the auxiliary positive electrode material is LiCo1-x-yNixMnyO2, wherein 0<x<0.9, 0<y<0.9, 0<x+y<0.9, and the LiCoO2 is a modified LiCoO2 coated with an Al2O3 film. The overcharge performance of the batteries can be significantly increased and the use amount of the overcharge additive can be reduced by using the positive electrode material so as to its improve the cycle performance of the batteries and improve the anti-overcharge safety in the special applications and the charging conditions.

Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.

Abstract: The invention provides a methoxypoly(ethylene glycol)-poly(lactide) block copolymer capped with phenylalanine group. The block copolymer is represented by formula (I), wherein R is acyl amine group, a=20-200, b=5-50; and molecular weights of the ethoxypoly(ethylene glycol) block component and the poly(lactide) block component respectively range from 1000-5000 and 1000-10000. The preparation method and use of the block copolymer are also provided.

Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.

Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.

Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.

Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.

Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.

Abstract: Provided are a positive electrode material for lithium ion batteries and a process for preparing the same. The positive electrode material for lithium ion batteries comprises a composite positive electrode material consists of LiCoO2 and an auxiliary positive electrode material, the general formula of the auxiliary positive electrode material is LiCo1?x?yNixMnyO2, wherein 0<x<0.9, 0<y<0.9, 0<x+y<0.9, and the LiCoO2 is a modified LiCoO2 coated with an Al2O3 film. The overcharge performance of the batteries can be significantly increased and the use amount of the overcharge additive can be reduced by using the positive electrode material so as to its improve the cycle performance of the batteries and improve the anti-overcharge safety in the special applications and the charging conditions.

Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.

Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.